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Background/Aims: When undergoing endoscopic submu-
cosal dissection (ESD), patients with liver cirrhosis (LC) may 
suffer from a high risk of bleeding, bacteremia and tissue 
vulnerability. There have been few reports evaluating the ef-
ﬁ  cacy and safety of ESD in patients with LC. Methods: From 
January 2004 to March 2010, 23 patients with LC (cirrhosis 
group) underwent ESD for superficial gastric neoplastic le-
sions. The number of patients with a liver function in the 
Child-Pugh classes A and B were 20 and 3, respectively. The 
clinical outcomes and complications were compared with 
69 patients without LC (control group) that were matched for 
age and sex. Results: The en bloc resection, R0 resection 
and en bloc plus R0 resection rates of the cirrhosis group 
were 82.6%, 91.3%, and 82.6%, respectively, and did not 
show significant differences from the rates of the control 
group. No local recurrence was found in either group during 
the follow-up period. The procedure length of time (41.0 vs 
39.0 minutes), rate of bleeding (4.3% vs 7.2%) and rate of 
perforation (0.0% vs 1.4%) in the cirrhosis group were also 
comparable to the results from the control group. Conclu-
sions: ESD was safely performed in patients with LC, and 
satisfactory outcomes were achieved with high en bloc and 
R0 resection rates for superﬁ  cial gastric neoplastic lesions. 
(Gut Liver 2012;6:58-63)
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INTRODUCTION
Endoscopic mucosal resection (EMR) has become a standard 
treatment for superficial gastric neoplastic lesion including gas-
tric dysplasia and early gastric cancer (EGC) because of its mini-
mal invasiveness and excellent long-term survival comparable 
to surgical resection.
1-3 To achieve an accurate and reliable his-
topathological evaluation after EMR, en bloc resection is desir-
able.
4 As EMR method uses snare, however, a trial of resecting 
lesions larger than 2.0 cm may result in piecemeal resections.
5,6
To overcome the size limitation of EMR and consequently to 
improve en bloc resection rate, endoscopic submucosal dissec-
tion (ESD) method was recently developed and has been widely 
accepted these days in Far Eastern countries.
7-11 As electrosurgi-
cal knife is used instead of snare and the submucosa beneath 
the lesion is directly dissected in ESD, there is theoretically no 
limitation in lesion size that can be resected in en bloc fashion. 
However, as ESD is highly advanced technique, it requires lon-
ger procedure time and can cause higher rate of complications 
such as bleeding and perforation compared to conventional 
EMR.
4,7,8 Bleeding is the most common complication occurring 
in ESD and the rate is reported to be up to 15%.
12
Patients with liver cirrhosis (LC) are exposed to high risk of 
bleeding in case of invasive treatments such as ESD because 
of low platelet count and coagulopathy accompanying LC.
13 
In addition, high rate of procedure-associated bacteremia is 
reported
14-16 and vulnerability of tissue in portal hypertensive 
gastropathy also make them poor candidates for ESD. Therefore, 
patients with LC might be regarded as a distinct entity with high 
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complication of ESD in these patients need to be evaluated. To 
date, however, there have been few reports evaluating the ef-
ficacy and safety of ESD in patients with LC.
17
In the present study, we compared the outcomes and com-
plications of ESD in patients with and without LC and aimed to 
evaluate the feasibility and safety of ESD for superficial gastric 
neoplastic lesions in patients with LC. 
MATERIALS AND METHODS
1. Patients
From January 2004 to March 2010, a total of 2,568 gastric 
ESD procedures were performed at Samsung Medical Center 
to remove superficial gastric neoplastic lesions (1,415 ESDs for 
EGCs and 1,153 ESDs for gastric dysplasias) and all these cases 
were consecutively collected in our database. Among them, 23 
patients had LC and were enrolled in this study: 4 low grade 
gastric dysplasias, 4 high grade gastric dysplasias, and 15 EGCs. 
The grade of gastric dysplasia and carcinoma was determined 
according to the Vienna classification of gastrointestinal epithe-
lial neoplasia: LGD in category 3, HGD in category 4, and in-
tramucosal and submucosal carcinoma in category 5.
18 Patients 
were diagnosed to have LC based on the radiologic findings, 
clinical data with laboratory investigation and medical history 
implying portal hypertension such as esophageal or gastric 
varix or ascites (Fig. 1).
19,20 Patients’ liver function was classified 
according to the Child-Pugh class: 20 patients in Child-Pugh 
class A and 3 patients in Child-Pugh class B. Table 1 summa-
rizes the cirrhosis-associated features of these patients. 
Therapeutic efficacy and complication of ESD were compared 
between patients with LC (cirrhosis group) and without LC (con-
trol group). Control groups were matched for age and sex and 
randomly selected in the ratio of 1:3 from the patients without 
LC who underwent ESDs for superficial gastric neoplastic le-
sions from January 2004 to March 2010. 
Informed consent was obtained from each patient included in 
the study. The study protocol conforms to the ethical guidelines 
of the Declaration of Helsinki in 1995 as reflected in a priori ap-
Fig. 1. A case of a 60-year-old male 
patient with liver cirrhosis who un-
derwent endoscopic submucosal dis-
section for early gastric cancer. His 
serum platelet count was 140×10
3/
μL, and his Child-Pugh liver func-
tion classification was A (serum 
albumin, 3.5 g/dL; serum bilirubin, 
1.7 mg/dL; prothrombin time in INR, 
1.27). (A) Surface irregularity of the 
liver and marked gastric fundic varix 
(white arrow) is observed with ab-
dominal computed tomography. (B) 
Gastric fundic varix is shown with 
upper endoscopy. (C) A 0.6-cm type 
0-IIc lesion is observed at the lesser 
curvature side of the midbody. (D) A 
large, artificial, ulcer-induced after 
endoscopic submucosal dissection.
Table 1. Cirrhosis-Associated Features of the 23 Patients with Liver 
Cirrhosis Who Underwent Endoscopic Submucosal Dissection for Su-
perficial Gastric Neoplastic Lesions
Feature No. (%)
Etiology of liver cirrhosis HBV infection 16 (69.6)
HCV infection   2 (8.7)
Non-B non-C   5 (21.7)
Child-Pugh class A 20 (87.0)
B   3 (13.0)
C   0 (0.0)
Ascites   3 (13.0)
Encephalopathy   0 (0.0)
Endoscopic findings implying Esophageal varix   7 (30.4)
  portal hypertension Gastric varix   3 (13.0)
Portal hypertensive 
  gastropathy
  2 (8.7)
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proval by the institution’s human research committee. 
2. ESD
All ESD procedures were carried out under conscious sedation 
with the intravenous administration of midazolam combined 
with pethidine. Doses of drugs were adjusted according to the 
patients’ condition. The average amounts of midazolam used 
were 3.6±1.0 mg and 3.8±1.3 mg in LC and control groups, 
respectively (p=0.494). The average amounts of pethidine used 
were 43.5±13.5 mg and 46.0±10.2 mg in LC and control groups, 
respectively (p=0.427). Before procedure, three patients with 
LC received platelet transfusion and one patient received fresh 
frozen plasma transfusion. All three patients receiving platelet 
transfusion had liver function of Child-Pugh class A. Before 




3/μL, respectively. After transfusion, plate-




μL, respectively. One patient receiving fresh frozen plasma had 
liver function of Child-Pugh class B. Before transfusion, pro-
thrombin time of this patient was 2.2 in international normal-
ized ratio (INR) and it was corrected to 1.6 after fresh frozen 
plasma transfusion. Taking aspirin, warfarin, and nonsteroidal 
anti-inflammatory drug were prohibited at least 1 week before 
procedure. Prophylactic antibiotics were not prescribed before 
procedure.
ESD was performed as previously described in detail.
9 In brief, 
marking dots were made circumferentially at approximately 
5 mm lateral to the margin of the lesion using a needle knife 
(KD-1L-1, Olympus, Tokyo, Japan; Needle papillotome, MTW 
Endoscopy, Wesel, Germany). After marking, a submucosal 
injection of saline or glycerin solution mixed with epinephrine 
and indigocarmine was performed around the lesion to lift it off 
the muscle layer. Then, an initial incision of mucosa was made 
with the needle knife to allow insertion of the tip of the knife 
into the submucosa. After the initial incision, a circumferential 
mucosal incision was performed outside the marking dots to 
separate the lesion from the surrounding non-neoplastic mu-
cosa. This step was done using the electrosurgical knife such as 
needle, Flex (KD-630L; Olympus) or insulated-tipped (IT) knife 
(KD-610L; Olympus) with a high-frequency generator (Erbotom 
ICC 200; ERBE Elektromedizin Ltd., Tübingen, Germany). After 
the circumferential incision, an additional submucosal injec-
tion was performed beneath the lesion. Finally, the submucosal 
connective tissue just beneath the lesion was directly dissected 
using an electrosurgical knife such as needle, Flex or IT knife.
Hemostatic forceps (FD-410LR; Olympus) or hemoclips were 
used to control bleedings during and after resection. During and 
until 1 day after procedure, ranitidine was given via parental 
route and then standard dose of proton pump inhibitor was pre-
scribed for 4 weeks. 
3. Assessment of the therapeutic efﬁ  cacy and complication
En bloc resection was defined as resection in one piece with-
out fragmentation. R0 resection was defined as resection with 
tumor-free lateral and vertical resection margins.
9
The procedure time was defined as the required time for 
marking, precutting, submucosal dissection and hemostasis. 
Bleeding was defined as 1) intraoperative massive bleeding 
that required blood transfusion, 2) postoperative bleeding that 
required blood transfusion or endoscopic or surgical interven-
tion because of hematemesis or melena, or 3) a decrease of the 
hemoglobin level more than 2 g/dL after the procedure.
9
Perforation was diagnosed when mesenteric fat or intra-
abdominal space was directly observed during the procedure 
(frank perforation) or free air was found on a plain chest X-ray 
after the procedure without a visible gastric wall defect during 
the procedure (microperforation).
9,21
4. Follow-up after ESD
The patients were followed up with an upper endoscopy with 
a biopsy 2 months after ESD to confirm healing of the artificial 
ulcer and to exclude the presence of any residual tumor. Then, 
upper endoscopy was performed every 6 months for 3 years to 
check for local or metachronous recurrence. From the fourth 
year, upper endoscopy was performed annually. For patient 
with EGC, an abdominal computed tomography was also per-
formed every 6 months for 3 years and then performed annu-
ally to detect extragastric recurrence. 
5. Statistical analysis
Continuous data were analyzed using the Student’s t-test. 
Categorical data analysis was done by χ
2 test or Fisher’s exact 
test. All p-values were 2-tailed and p-values less than 0.05 were 
considered statistically significant. 
RESULTS
Table 2 summarizes the clinicopathologic characteristics of 
cirrhosis group and control group. No significant difference was 
found in age, gender, location, tumor size, specimen size, or 
tumor depth. However, cirrhosis group showed significant dif-
ference from control group in platelet count, prothrombin time, 
bilirubin, and albumin levels. Among patients enrolled, neither 
cirrhosis nor control group had ulcerative lesion.
Table 3 summarizes the clinical outcomes of ESD in cirrhosis 
and control group. En bloc resection rate, R0 resection rate and 
en bloc plus R0 resection rate of cirrhosis group were 82.6%, 
91.3%, and 82.6%, respectively and did not show significant 
difference from those of control group. All four lesions not 
achieving en bloc plus R0 resection in cirrhosis group were 
EGCs and were resected in piecemeal fashion. The Child-Pugh 
classification was A in all four cases. Among these four cases, Choi JH, et al: ESD in Patients with Cirrhosis  61
two cases showed positive resection margins and underwent ad-
ditional gastrectomy. Two cases with negative resection margin 
did not show residual cancer in follow-up upper endoscopy. 
Procedure time of cirrhosis group was also comparable to that 
of control group.
For ESD-associated complication, no significant difference 
was observed in bleeding rate or perforation rate between two 
groups. Only one case of bleeding was reported in cirrhosis 
group. This patient showed melena and hematemesis 5 days 
after ESD. On emergency endoscopy, active bleeding was found 
and hemostasis was successfully achieved using hemoclips. 
This patient’s Child-Pugh class was B and platelet count was 
105×10
3/μL. Before ESD, 6 units of fresh frozen plasma were 
transfused to correct prothrombin time. Prothrombin time in 
INR was 1.6 at the time of procedure. In this study, no patients 
in cirrhosis group underwent perforation during procedure. No 
increase in ascites, no development of hepatic encephalopathy, 
no worsening of liver function occurred after ESD. However, 
fever developed one day after ESD in two patients in cirrhosis 
group. In these two patients, fever was successfully controlled 2 
days after ESD with treatment. Blood cultures showed negative 
result in both patients. 
Among patients without undergoing additional treatment af-
ter ESD, median duration of follow up was 17.5 months (range, 
2 to 72 months) for cirrhosis group and 26.0 months (range, 5 
to 60 months) for control group, respectively. No local recur-
rence was found in either group during follow-up period.
DISCUSSION
In case of abdominal surgery, patients with LC often undergo 
severe complication such as hepatic failure, massive ascites, 
intra-abdominal bleeding, multi-organ failure, and sepsis.
13,22 
Some studies reported high mortality rate of up to 30% in these 
patients.
23,24 Therefore, patients with LC are currently regarded 
as a distinct entity with high complication rate for abdominal 
open surgery. Although far less invasive compared to surgery, 
ESD also carries the potential risk of severe complication in pa-
tient with LC because of low platelet count, coagulopathy, high 
rate of bacteremia, and vulnerability of tissue due to portal hy-
pertensive gastropathy. Therefore, it is required to elucidate the 
clinical outcomes and complication of ESD in patients with LC. 
In the present study, en bloc resection rate, R0 resection 
rate and en bloc plus R0 resection rate of cirrhosis group were 
82.6%, 91.3%, and 82.6%, respectively and did not show signif-
icant difference from those of control group without cirrhosis. 
No local recurrence was found in either group during follow-
up period. In addition to these favorable outcomes, bleeding 
and perforation rates in cirrhosis group was also comparable to 
those of control group. 
In this study, only one case of bleeding was reported in cir-
rhosis group. This patient showed melena and hematemesis 5 
days after ESD and his liver function was classified as Child-
Pugh class B. Ogura et al.
17 reported the similar trend in their 
case report about ESD in patients with LC. In their case report, 
bleeding rate after ESD was 20% and all the patients undergo-
ing bleeding showed severe liver dysfunction of Child-Pugh 
class B.
17 It is well known that open gastrectomy is associated 
with high complication and mortality rates in patients with 
severe liver dysfunction. Jang et al.
22 reported the clinical out-
comes after curative surgery for gastric cancer in patients with 
Table 3. The Comparison of the Clinical Outcomes between Patients 
with and without Cirrhosis Who Underwent Endoscopic Submucosal 







En bloc resection  19 (82.6) 65 (94.2) 0.104
R0 resection  21 (91.3) 68 (98.6) 0.153
En bloc+R0 resection 19 (82.6) 64 (92.8) 0.220
Procedure time, min 41.0±26.1 39.0±18.1 0.384
Bleeding  1 (4.3) 5 (7.2) 1.000
Perforation  0 (0.0) 1 (1.4) 1.000
Data are presented as mean±SD or number (%).
Table 2. The Comparison of the Clinicopathologic Characteristics 
between Patients with and without Cirrhosis Who Underwent Endo-










Age, yr 61.3±5.2 61.2±3.1  0.911
Gender 
   Male 17 (73.9) 51 (73.9)  1.000
   Female  6 (26.1) 18 (26.1)
Laboratory data
   Platelet count, ×10
3/μL 106.7±37.8 222.5±42.4
   Prothrombin time, INR 1.2±0.2  1.0±0.1 <0.001
   Bilirubin, mg/dL 1.1±1.0  0.5±0.3 <0.001
   Albumin, g/dL 3.7±0.5  4.1±0.3  0.014
Location 
   Antrum or angle 17 (73.9) 52 (75.4)  0.839
   Body  6 (26.1) 16 (23.2)
   Fundus or cardia 0 (0) 1 (1.4)
Tumor size, cm 1.4±0.9  1.6±1.0  0.578
Specimen size, cm 4.0±1.4  4.4±1.5  0.246
Tumor depth
   Mucosa 18 (78.3) 56 (81.2)  0.442
   Submucosal invasion <500 μm 1 (4.3)  7 (10.1)
   Submucosal invasion ≥500 μm  4 (17.4) 6 (8.7)
Data are presented as mean±SD or number (%).62  Gut and Liver, Vol. 6, No. 1, January 2012
LC. In their study, postoperative ascites (63.6% vs 13%) and 
hepatic encephalopathy (36.4% vs 4.3%) occurred significantly 
more frequently in patients with Child-Pugh class B or C than 
in those with class A. In addition, postoperative mortality in pa-
tients with Child-Pugh class B or C was significantly higher as 
compared with Child-Pugh class A (27.2% vs 4.3%).
22 Although   
the present study showed favorable result of ESD in patients 
with LC, more caution and further studies are warranted for ESD 
in patients with severe liver dysfunction (Child-Pugh class B or 
C).
In our study, two patients in cirrhosis group showed fever af-
ter ESD. As risk for bacteremia associated with gastrointestinal 
bleeding is well established in patients with LC,
25 prophylactic 
administration of antibiotics is currently recommended for all 
LC patient with acute bleeding regardless of endoscopic proce-
dure.
16 However, there has been no study on the frequency of 
bacteremia in patients with LC undergoing ESD. In addition, 
several studies reported the low rate of bacteremia after EMR 
or ESD.
26,27 Blood culture results were negative in both patients 
with fever in the present study. Therefore, necessity for antibiot-
ics prophylaxis is still unclear in patients with LC undergoing 
ESD and further study is required.
The present study had several limitations. It was a retrospec-
tive study performed in a single center and the number of 
patients with Child-Pugh Class B or C was small. Follow-up 
duration after ESD was relatively short to confirm long-term 
outcomes.
In conclusion, the result of the present study indicated that 
even in patients with LC, ESD could be safely performed and 
could achieve satisfactory outcomes with high en bloc and R0 
resection rate for superficial gastric neoplastic lesions. Given the 
small number of patients with Child-Pugh class B or C included 
in this study, further large study is required to confirm the effi-
cacy and safety of ESD in patients with severe liver dysfunction.
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